Navigation Links
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
Date:5/8/2008

od, palpitations,

breathing difficulties, sleep disturbances, restlessness, and other

physical symptoms.(9)

References

1. National Institute of Mental Health: Anxiety Disorders. NIH

Publication No. 06-3879. Available at: (Due to URL length, please copy and paste into browser) http://www.nimh.nih.gov/health/publications/anxiety-disorders/generalized- anxiety-disorder-gad.shtml
Accessed March 20, 2008.

2. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,

Text Revision. Washington, DC: American Psychiatric Association;

2000:472-475.

3. Rickels K and Ryann M. Pharmacotherapy of Generalized Anxiety

Disorder. J Clin Psychiatry. 2002;63 (suppl 14): 9-16.

4. Schmitt R, Gazalle FK, Silva de Lima M, et al. The efficacy of

antidepressants for generalized anxiety disorder: a systematic review

and meta-analysis. The Brazilian Journal of Psychiatry. 2005;

27(1):18-24.

5. Data on File, DA-SXR-15, AstraZeneca LP.

6. Joyce M, Khan A, Atkinson S, et al. Efficacy and safety of extended

release Quetiapine fumarate (quetiapine XR) monotherapy in patients

with generalized anxiety disorder (GAD) [poster]. Presented at: The

Annual Meeting of the American Psychiatric Association; May 3-8, 2008,

Washington, D.C., USA.

7. Chouinard G, Bandelow B, Ahokas A, et al. Once-daily extended release

of quetiapine fumarate (quetiapine XR) monotherapy in generalized

anxiety disorder: a Phases III, double-blind, placebo-controlled study

[poster]. Presented at: The Annual Meeting of The American College of

Neuropsychopharmacology; December 9-13, 2007, Boca Raton, FL.

8. Katzman M, Brawman-Mintzer O, Reyes E, et al. Extended Release'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
8. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
9. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...Patients in Cohort 3 Demonstrated Improvement in T...rapeutic Potential of HspE7, SAN DIEGO, May 12 /P...Corporation (TSX: NVN) today announced positive im...ing Phase 1 clinical trial of its lead product,can...helial neoplasia, or,CIN, a precursor to cervical ...
(Date:5/9/2008)...A, Fla., May 9 /PRNewswire-USNewswire/ -- Osteoart...ondition that affects almost 50,million people in ...f,cartilage in bone joints. The novel investigatio... oral analgesic, provided significant relief,for p... treated with,placebo, and with fewer gastrointest...
(Date:5/9/2008)...TTLE, May 9 /PRNewswire-USNewswire/ -- The risk of...n prostatic hyperplasia (BPH), can be,reduced by c...ntaining a,normal weight and eating a healthy diet...cer Prevention Program at Fred Hutchinson Cancer R...ies that suggest men need not,feel helpless agains...
(Date:5/9/2008)...th International Phase III Study Shows Positive Re...ata -, NUTLEY, N.J., May 9 /- Roche ...ar Phase III study showing that ACTEMRA(TM),(tocil...tructural damage to,joints in patients with rheuma...veness of an RA treatment. The study also demonstr...
Breaking Medicine Technology:Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 5Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 6Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 2Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 3Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5Memory in artificial atoms 4445 1Memory in artificial atoms 4445 2Faster Test Detects Fake Tamiflu Drugs 16192 1Faster Test Detects Fake Tamiflu Drugs 16192 2Chehalis Tribes Announce Benefit to Help Returning Combat Veterans 16187 1Chehalis Tribes Announce Benefit to Help Returning Combat Veterans 16187 2Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 16183 1Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 16183 2Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 16183 3
... Vaginal Supplement Studied in Largest-Ever IVF Tr...PRNewswire/ -- Results of,four studies evaluating ...ogesterone vaginal insert in development for lutea...t for implantation and,the early stages of pregnan...re presented at the 55th Annual Meeting of the,Pac...
... N.J., April 18, 2007 /PRNewswire-FirstCall/ --,ON...rug candidate,may have potential as a chemopreven...ma researcher Michele Carbone M.D., Ph.D.,at this...AACR),Annual Meeting. , In a series of poster pres...ldwide problem of asbestos exposure and its link t...
Other Medicine Technology:Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 2Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 3Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 4Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 5Onconase has Potential as Chemopreventive Agent in Mesothelioma,Reports World-Renowned Mesothelioma Researcher at AACR Annual,Meeting 2Onconase has Potential as Chemopreventive Agent in Mesothelioma,Reports World-Renowned Mesothelioma Researcher at AACR Annual,Meeting 3Onconase has Potential as Chemopreventive Agent in Mesothelioma,Reports World-Renowned Mesothelioma Researcher at AACR Annual,Meeting 4
(Date:5/13/2008)... HARBIN, China, May 13 /Xinhua-PRNewswire-FirstCa...oard: CSKI), a manufacturer, marketer and,distribu...oducts in China,today announced that it will cond... May 15, 2008 to discuss its first quarter 2008 fi...man, CEO and Director of China Sky One,Medical, In...
(Date:5/13/2008)...ildbearing had no such benefit if baby was bottle-...13 (HealthDay News) -- Women who breast feed for m...arthritis (RA) by half, according to a new Swedish...g children but not breast-feeding offered women no...contraceptives also failed to reduce the risk of R...
(Date:5/13/2008)...NEW YORK (May 13, 2008) -- Promising results from ...ell Medical Center physician-scientists show that ... the progression of Batten disease, or Late Infant..., genetic, degenerative neurological disorder that... to 12. , The clinical trial found that the pro...
(Date:5/13/2008)... SALT LAKE CITY, May 13 /PRNewswire/ -- Paramed S...ent of their marine-grade Mobility Offers,Versatil...chair to oil and,gas platform operators in the Gul...platforms will enable the safe and timely evacuati...atform., Paramed developed the dual-track MOV in ...
Breaking Medicine News(10 mins):Health News:China Sky One Medical, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Breast-feeding Might Shield Women From Rheumatoid Arthritis 2Health News:NYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease 2
...ltinational team of researchers based in the UK ha...s biological barriers, opening up the potential fo...rchers from the School of Pharmacy, University of ...otubes by adding a range of different functional g...
...U.S. Food and Drug Administration (FDA) today clea... device that can help save the arms and legs of so...ndividuals in other trauma settings and emergency ... Limb Salvage Shunt (TLSS), made by Vascutek Ltd. ...
...a's drug major Ranbaxy Laboratories has received t...pproval to manufacture// and market its formulatio...in adults. Ranbaxy Pharmaceuticals Inc. (RPI), a ...oratories Limited (RLL), announced Friday that FDA...
...he recent years, scientists discovered a family of...xtend life in organisms// as diverse as yeast, wor...t The Wistar Institute points to another strategy ...ir anti-aging powers. They may also be able to con...
Other Medicine News:Health News:Carbon Nanoneedles For Drug Delivery 2Health News:Carbon Nanoneedles For Drug Delivery 3Health News:Carbon Nanoneedles For Drug Delivery 4Health News:FDA Clears Critical Limb-Saving Vascular Device 2Health News:Anti-Aging Powers of Enzyme Sirtuins 2
VG2 PLIF Allograft is comprised of two cortical planks of bone surrounding a cancellous center. The cortical planks provide strength for anterior column support. The cancellous bone provides a lattic
Williams Micro Discectomy Instruments are designed to be used in the microsurgical treatment of herniated disks.
Meyerding Laminectomy Retractors, self-retaining.
Karlin Crank Frame Spinal Retractor Set is designed for posterior lumbar and thoracic spine surgery. Arm design allows the blades be pre-positioned in the wound prior to attachment.
Medicine Products: